BG Medicine gets $40mm through its Series D round

BG Medicine (molecular diagnostics) has raised $40mm through the closing of its Series D venture round. New investors Legg Mason Capital Management, GE Asset Management, and SmallCap World Fund were joined by returning backers Flagship Ventures, Gilde Healthcare Partners, Humana, and individual investor Stelios Papadopoulos. Leerink Swann was the placement agent. The company, which has raised about $92mm since it was established in 2000, will use the funds to finish development of and market its first two diagnostics--one to distinguish between which heart-failure patients will remain stable and which ones will quickly decline, and another test to determine those that may be at risk of heart attack in the next 2-3 years.